Q3 2025 Teva Pharmaceutical Industries Ltd Earnings Call Transcript

Nov 5, 2025 / 01:00 PM GMT

Release Date Price: €21.6 (+23.78%)

Transcript 10-Q8-K

Key Points

Positve

Teva Pharmaceutical Industries Ltd (TEVA) reported its 11th consecutive quarter of growth, with a 3% increase in revenue to $4.5 billion.
The company's innovative products showed strong performance, with Estero growing 38% and Ajovi up 19%.
Teva's net debt to EBITDA ratio is now below 3 times for the first time since 2016, indicating improved financial health.
The company is on track to achieve its 2027 revenue target of $2.5 billion for Estero, with peak sales expected to exceed $3 billion.
Teva's transformation program is progressing well, with $70 million in savings achieved in 2025 and a target of $700 million by 2027.

Negative

Teva's global generics revenue is expected to be flat in local currency compared to 2024, due to tough year-over-year comparisons and market softness.
The company's free cash flow decreased significantly to $15 million in Q3 2025 from $922 million in Q3 2024, mainly due to timing of sales and higher legal settlement payments.
Teva's European generics business declined by 5%, impacted by tough comparisons from the prior year.
The sale process for Teva's Tapi unit did not result in a transaction, and the company is now exploring alternative options.
There is uncertainty around potential US tariffs on pharmaceuticals, which could impact Teva's financial outlook.

Refinitiv StreetEvents Event Transcript
P R E L I M I N A R Y V E R S I O N

TEVA.TA - Teva Pharmaceutical Industries Ltd
Q3 2025 Teva Pharmaceutical Industries Ltd Earnings Call
Nov 05, 2025 / 01:00PM GMT

=====================
Conference Call Participants
=====================
* >>NOTE
* >>Transcription Start

=====================
Presentation
--------------------------------------------------------------------------------
>>NOTE [1]
--------------------------------------------------------------------------------

THIS TRANSCRIPT IS THE INITIAL PRELIMINARY VERSION WHICH LEVERAGES MACHINE LEARNING TECHNOLOGY. AS SUCH, PLEASE BE AWARE THERE MAY BE INACCURACIES IN THE TEXT DISPLAYED. FUTURE EDITED VERSIONS WILL BE REVIEWED FOR GREATER ACCURACY.

--------------------------------------------------------------------------------
>>Transcription Start, [2]
--------------------------------------------------------------------------------

Hello and welcome to the Q3 2025 Tether Pharmaceutical Industries Limited earnings conference

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.